Evidence map›Paper›PMID 20485304›Full record

Trial reportEuropean journal of clinical nutrition2010

Use of a fermented dairy probiotic drink containing Lactobacillus casei (DN-114 001) to decrease the rate of illness in kids: the DRINK study. A patient-oriented, double-blind, cluster-randomized, placebo-controlled, clinical trial.

D Merenstein, M Murphy, A Fokar, R K Hernandez, H Park, H Nsouli, M E Sanders, B A Davis, V Niborski, F Tondu and 1 more

3 registry-linked trialsAbstract readRandomized Controlled Trial
In one paragraph

Trial report in European journal of clinical nutrition, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 51 papers, 11 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 11 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02687503 nacompletednot on this mapstarted 2017, after this paper: background citation

Impact of Probiotic Use on Immune Cell Function in Children

TypeinterventionalSponsorUniversity of Wisconsin, MadisonRan2017 to 2019Enrolled23ConditionsRespiratory Tract InfectionsArmsProbiotic
NCT03377374 nacompletednot on this mapstarted 2017, after this paper: background citation

Randomized Controlled Trial on the Safety and Efficacy of L. Reuteri ATCC PTA 5289 & L. Reuteri DSM 17938 for the Treatment of Children With Pharyngitis and/or Tonsillitis: A Proof of Concept

TypeinterventionalSponsorInnovacion y Desarrollo de Estrategias en SaludRan2017 to 2019Enrolled70ConditionsPharyngitis, TonsillitisArmsProbiotic, Placebo
NCT05484102 nacompletednot on this mapstarted 2022, after this paper: background citation

Preventive Effect of Cow's Milk Fermented With Lactobacillus Paracasei CBA L74 on Upper Respiratory Tract and Gastrointestinal Infectious Diseases in Children: a Double-blind, Randomized, Placebo-controlled Trial

TypeinterventionalSponsorUniversity of BariRan2022 to 2024Enrolled200ConditionsUpper Respiratory Tract Infections, Gastrointestinal Infection, Children, OnlyArmsmilk fermented with lactobacillus paracasei CBA L74, placebo milk formula
3 · Its place in the literature

Who cites it

51 citing papers in PubMed, 11 syntheses or guidelines pooled it.

  1. Pooled it
  2. Probiotics for preventing acute upper respiratory tract infections.The Cochrane database of systematic reviews · 2022
    Pooled it
  3. Pooled it
  4. The effect of probiotics on respiratory tract infection with special emphasis on COVID-19: Systemic review 2010-20.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Probiotics for preventing acute otitis media in children.The Cochrane database of systematic reviews · 2019
    Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

D MerensteinDepartment of Family Medicine, Georgetown University Medical Center, Washington, DC 20007, USA. djm23@georgetown.edu
M Murphy
A Fokar
R K Hernandez
H Park
H Nsouli
M E Sanders
B A Davis
V Niborski
F Tondu
N M Shara

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo evaluate whether a fermented dairy drink containing the probiotic strain Lactobacillus casei DN-114 001 could reduce the incidence of common infectious diseases (CIDs) and the change of behavior because of illness in children. SUBJECTS/

methodsWe conducted a double-blinded, randomized, placebo-controlled allocation concealment clinical trial in the Washington, DC metropolitan area. Participants were 638 children 3-6 years old in daycare/schools. The intervention was a fermented dairy drink containing a specific probiotic strain or matching placebo with no live cultures for 90 consecutive days. Two primary outcomes were assessed: incidence of CIDs and change of behavior because of illness (both assessed by parental report).

resultsThe rate of change of behavior because of illness was similar among active and control groups. However, the incidence rate for CIDs in the active group (0.0782) is 19% lower than that of the control group (0.0986) (incidence rate ratio=0.81, 95% CI: 0.65, 099) P=0.046.

conclusionsDaily intake of a fermented dairy drink containing the probiotic strain L. casei DN-114 001 showed some promise in reducing overall incidence of illness, but was primarily driven by gastrointestinal infections and there were no differences in change of behavior.

Indexed as

Communicable Disease ControlLacticaseibacillus caseiChildChild, PreschoolCommunicable DiseasesDairy ProductsDistrict of ColumbiaDouble-Blind MethodFemaleFermentationGastrointestinal DiseasesHumansIncidenceMaleProbioticsRespiratory Tract Infections

Identifiers

PMID20485304
PMCPMC2906750

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.